Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis
Related Experiment Video
Updated: Dec 5, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Zhujun Deng1, Yun Qin2, Yongmei Liu3
1Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Precision Medicine Key Laboratory of Sichuan Province, Precision Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
Background:
Antiangiogenic agents combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are considered potentially effective biologically synergistic drug combinations for EGFR-mutant advanced non-small-cell lung cancer (NSCLC), although some controversy remains. The European Commission has approved the use of bevacizumab plus erlotinib as first-line treatment of EGFR-mutated NSCLC; however, it has not yet been approved by the U.S. Food and Drug Administration. Recently, several phase III, randomized controlled trials of combinations of antiangiogenic agents and EGFR-TKIs have been reported. These studies have not yet been included in any previous meta-analysis.
Materials And Methods:
We performed a meta-analysis to compare antiangiogenic agents plus EGFR-TKIs versus EGFR-TKIs alone for treatment of EGFR-mutant NSCLC. The main outcomes were progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), and adverse events (AEs).
Results:
We identified 9 previous reports of 6 randomized controlled trials and 1 prospective cohort study, involving 1295 patients. Compared with EGFR-TKIs alone, antiangiogenic agents plus EGFR-TKIs resulted in a higher PFS (hazard ratio, 0.58; 95% confidence interval [CI], 0.50-0.67; P < .001). However, no significant differences in OS (hazard ratio, 0.79; 95% CI, 0.53-1.18; P = .26) and ORR (risk ratio, 1.03; 95% CI, 0.97-1.10; P = .30) were found between the 2 groups. An increased risk of serious AEs (risk ratio, 1.41; 95% CI, 1.11-1.79; P = .005) was found in the combination drug therapy group.
Conclusions:
Antiangiogenic agents plus EGFR-TKIs enhanced PFS for patients with EGFR-mutant NSCLC but with a greater risk of serious AEs. No significant benefits for OS and ORR were found between the 2 groups.
Insights
Adding antiangiogenic agents to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) improved progression-free survival for EGFR-mutant non-small-cell lung cancer (NSCLC). However, this combination therapy increased the risk of serious adverse events without improving overall survival or response rates.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Combination therapy with antiangiogenic agents and EGFR TKIs is explored for EGFR-mutant NSCLC.
- Controversy exists regarding the efficacy and safety of these combinations.
- Recent Phase III trials have reported outcomes not yet included in meta-analyses.
Purpose of the Study:
- To compare the efficacy and safety of antiangiogenic agents plus EGFR TKIs versus EGFR TKIs alone in EGFR-mutant NSCLC.
- To evaluate progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs).
Main Methods:
- A meta-analysis was conducted on 6 randomized controlled trials and 1 prospective cohort study.
- In total, 1295 patients with EGFR-mutant NSCLC were included.
- Outcomes analyzed included PFS, OS, ORR, and AEs.
Main Results:
- Combination therapy significantly improved PFS (HR, 0.58; 95% CI, 0.50-0.67; P < .001).
- No significant differences were observed in OS (HR, 0.79; 95% CI, 0.53-1.18; P = .26) or ORR (RR, 1.03; 95% CI, 0.97-1.10; P = .30).
- A higher risk of serious AEs was noted with combination therapy (RR, 1.41; 95% CI, 1.11-1.79; P = .005).
Conclusions:
- Antiangiogenic agents plus EGFR TKIs enhance PFS in EGFR-mutant NSCLC.
- This combination therapy is associated with an increased risk of serious adverse events.
- No significant improvements in OS or ORR were demonstrated for the combination therapy.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and the Cell Cycle